

Pilot Trial of Low Dose Naltrexone and Quality of Life in MS

Bruce A.C. Cree\*, Elena Kornyeveva, and Douglas S. Goodin.

\*corresponding author

Multiple Sclerosis Center at UCSF

350 Parnassus Ave., Suite 908

San Francisco, CA 94117

bruce.cree@ucsf.edu

Accepted Preprint

## Abstract

Objective: To evaluate the efficacy of 4.5 mg nightly naltrexone on the quality of life of multiple sclerosis patients.

Methods: This single center, double-masked, placebo-controlled, crossover studied evaluated the efficacy of eight weeks of treatment with 4.5 mg nightly naltrexone (Low dose naltrexone or LDN) on self reported quality of life of MS patients.

Results: 80 subjects with clinically definite multiple sclerosis were enrolled and 60 subjects completed the trial. 10 withdrew before completing the first trial period: 8 for personal reasons, 1 for a non-MS related adverse event and 1 for perceived benefit.

Database management errors occurred in 4 other subjects and quality of life surveys were incomplete in 6 subjects for unknown reasons. The high rate of subject dropout and data management errors substantially reduced the trial's statistical power. LDN was well tolerated and serious adverse events did not occur. LDN was associated with significant improvement on the following mental health quality of life measures: a 3.3 point improvement on the Mental Component Summary score of the SF-36 ( $P=.04$ ), a 6 point improvement on the Mental Health Inventory ( $P<.01$ ), a 1.6 point improvement on the Pain Effects Scale ( $P=.04$ ) and a 2.4 point improvement on the Perceived Deficits Questionnaire ( $P=.05$ ).

Interpretation: LDN significantly improved mental health quality of life indices. Further studies with LDN in MS are warranted.

## Introduction

Naltrexone is a mu opiate receptor antagonist US FDA approved for treatment of opiate addiction. Naltrexone in low dose was found to enhance the pain relieving effects of opiate agonists<sup>1,2</sup> and also to be beneficial in opioid detoxification.<sup>3</sup> LDN is proposed to “normalize” endogenous endorphin levels and that this effect on endorphins might be beneficial in autoimmune disease. A small (N=17) open label study in Crohns disease found that LDN improved active disease as measured by the Crohns disease activity index.<sup>4</sup> An open label study in 40 primary progressive multiple sclerosis (MS) patients found that spasticity was significantly reduced after 6 months of treatment with LDN compared to baseline.<sup>5</sup> This study also found that LDN treatment increased lymphocyte intracellular B-endorphin concentrations over baseline values. MS patients who use off-label LDN anecdotally report that LDN improves their overall quality of life (QoL) and have wanted to have this proposition evaluated systematically. Based on interviews with five North American pharmacies known to compound LDN we estimate that several thousand MS patients currently use this LDN. Here we report the results of a patient-sponsored, randomized, placebo-controlled, crossover clinical trial that evaluated the impact of LDN on MS patient reported outcomes as measured by the multiple sclerosis quality of life inventory (MSQLI).<sup>6</sup>

## Patients and Methods:

### Study Design and Objectives

The current trial is a single center, randomized, double-masked, placebo-controlled, crossover study that evaluated whether 8 weeks of treatment with nightly 4.5 mg naltrexone improved the quality of life (QoL) of MS patients as measured by the MSQLI (Figure 1). This study was supported entirely by private contributions from MS patients and is the first patient funded controlled clinical study in MS. Patients were treated with either LDN or placebo for eight weeks, followed by a one week washout, followed by eight weeks of treatment with the alternate study drug. Thus, all subjects received eight weeks of treatment with both LDN and placebo, in either order, and were masked as to the order of treatment. The crossover design was selected because it was hypothesized that eight weeks of treatment with LDN might provide a short term symptomatic benefit. A one week washout was selected because of the half-life of naltrexone is 4 hours and its active metabolite, 6- $\beta$ -naltrexol, is 13 hours (package insert). Thus the serum level would be effectively zero after a one week washout. Furthermore, because the MSQLI asks subjects to report on their symptoms during the last 4 weeks, the shortest period of time that subjects would have been off of LDN if they had they received LDN during the first study period was 5 weeks. Patients completed the MSQLI at baseline and after each study period. The study was approved by the UCSF committee on human research.

#### Participation Criteria

80 patients between the ages of 18 and 75 with clinically definite multiple sclerosis (International Panel criteria) were enrolled utilizing the following inclusion/exclusion criteria. Subjects had to be willing to not change or start disease modifying, or symptomatic therapies, for the duration of the trial. Subjects currently treated with

interferon  $\beta$  (either interferon  $\beta$  -1b or interferon  $\beta$  -1a), glatiramer acetate, or not on disease modifying therapy were allowed entry in to the trial. Women of childbearing potential had to be willing to use a barrier method of contraception during the trial. Potential subjects were excluded from the study if they had started a disease modifying therapy within three months of entry, or received treatment with chronic opiate agonists, or were treated concurrently with both interferon and with glatiramer acetate, or took immune suppressive medications including natalizumab, or were pregnant, or were unable to read a computer screen and use a mouse, or were currently taking LDN.

#### Study drug

Placebo and naltrexone capsules were compounded by the UCSF investigational pharmacy. Treatment codes were maintained by the investigational pharmacy.

Concomitant medications and pill counts were assessed at each study visit. The MSQLI was administered using a web-based system developed by Quesgen.

#### Outcome measures

The MSQLI was administered at baseline, and then following each eight week period of study drug administration (Figure 1). The MSQLI<sup>6</sup> is a QoL assessment tool developed for MS composed of 11 rating scales: the Physical Component Summary (PCS) and Mental Component Summary (MCS) of the short form-36<sup>7,8</sup>, Mental Health Inventory (MHI), Pain Effects Scale (PES), Perceived Deficits Questionnaire (PDQ), Multiple Sclerosis Social Support Survey (MSSS), Modified Fatigue Impact Scale (MFIS), Impact of Visual Impairment Scale (IVIS), Bowel Control Scale (BWCS), Bladder Control Scale

(BLCS), and the Sexual Satisfaction Scale (SSS). Subjects were required to complete the MSQLI within a 2 day window from completion of each study phase, i.e. at eight weeks plus or minus two days. Subjects are asked to answer these surveys with regard to their relevant symptoms during the last 4 weeks. Adverse events and self reported relapses, if any, were documented at each study visit. The expanded disability status scale (EDSS)<sup>9</sup> was not assessed following the two treatment periods. Improvement in QoL is characterized by an increase in the scores of the PCS, MCS, MHI and MSSS and a decrease in scores for the MFIS, PES, PDQ, BWCS, BLCS, IVIS and SSS.

#### Statistical analysis

Because of the crossover design, the results were analyzed using a time series regression equation modeled for random effects and clustered by study subject. The pre-specified analysis adjusted for sex, age, disease course (relapse remitting, secondary progressive, primary progressive and relapsing progressive), current treatment (interferon beta, glatiramer acetate, or no DMT), race, baseline score and study drug order.

#### Results

80 subjects were enrolled. Eight subjects voluntarily withdrew during the first treatment phase for personal reasons such as the inability to complete the MSQLI during the required window. One subject withdrew during the first study period because of perceived efficacy of LDN; at the end of the study it was determined that this subject was initially treated with placebo. One withdrew secondary to ongoing symptoms from an unrelated pre-existing medical condition (an acoustic neuroma). There was no

correlation between study drug and subject withdrawals. 70 subjects completed both treatment periods; however, data from all three MSQLI assessments was available for only 60 subjects. Ten subjects were dropped from analysis because of database management errors in four subjects and six uncompleted surveys. That six subjects did not complete six surveys was not detected until after the trial was complete. The reason for these uncompleted surveys is not known. The MSQLI was administered using a web based system specifically developed for this trial and methods to insure completeness of data entry were not implemented at the time the trial was conducted. Because 10 subjects dropped out of the trial and data management errors occurred in another 10 subjects the statistical power of the trial was substantially weakened. However, we do not believe that this loss of information caused type I errors because nine of the ten subjects who dropped out did so for reasons unrelated to the study. Furthermore, the data management errors were random rather than systematic.

In the pre-planned analysis that adjusted for baseline covariates as well as an unadjusted analysis, 8 weeks of treatment with LDN significantly improved mental health quality of life indices measured by the MCS of the short form 36, the MHI, the PES and a favorable trend for the PDQ (Table 2 and Figure 1). Order of treatment with LDN or placebo did not influence the outcome. Indeed, the only baseline covariate that had a statistically significant impact on the model was the baseline score although the relatively small sample size precluded detection of subtle influences. An impact on physical quality of life indices including the PCS of the short form 36, the MFIS, as well as the BWCS and

BLCS, SSS, and IVIS was not observed. Concurrent treatment with interferon  $\beta$  or glatiramer acetate did not influence these outcomes. Figure 1 also demonstrated a prominent placebo effect in this study. To emphasize the preliminary nature of this small single center study, a sensitivity analysis was conducted in which the 10 subjects who dropped out of the trial were included imputing their baseline scores for the MSQLI assessments following both study drug periods. This introduces 16.7% noise into the statistical analysis and causes the MCS of the SF-36, the PES and the PDQ observations favoring LDN to no longer be statistically significant; however, statistical significance is retained for the MHI ( $p=.043$ ).

MS relapses were not reported by any patient during the study. For the 60 subjects who completed the study adherence to the treatment protocol as measured by self reporting and pill counts was excellent. The average medication possession ratio was 95.7%.

Serious adverse events were not reported. The only potentially treatment related adverse event was vivid dreaming reported in 7 placebo and 10 LDN treatment periods. Other adverse events reported in each treatment period were: fatigue (2 placebo and 1 LDN), flu-like symptoms (1 placebo), insomnia (1 placebo), loss of appetite (1 LDN) and sinus infection (1 LDN). Euphoria was not reported by any patient.

## Discussion

This is the first randomized, placebo-controlled study of LDN in MS and the first patient funded clinical trial in MS. Eight weeks of treatment with LDN was associated with improvement in all of the self reported mental health outcome measures but not of the

physical outcome measures of the MSQLI. That mental health outcome measures improved during a relatively short course of treatment with LDN suggests that LDN has a symptomatic effect in MS. These observations are consistent with anecdotal patient reports suggesting that LDN makes patients “feel better”.<sup>10</sup> It is possible that LDN increases  $\beta$  endorphin levels<sup>5</sup> and that this may correlate with improvement in mental health QoL. That LDN did not have an impact on self reported physical functioning is to be expected because of the short duration of treatment. Whether LDN has benefit beyond 8 weeks of treatment, and whether LDN might improve physical functioning with extended treatment, are questions unanswered by this study design.

Benefits with respect to physical functioning might be anticipated from disease modifying therapies that reduce neurological disability. However, that some patients will continue to accumulate neurological impairment despite treatment may confound this prediction. Indeed, studies with interferon  $\beta$ , an immunomodulatory drug known to reduce the risk of neurological disability in MS, have not shown a consistent improvement in MS QoL.<sup>11-17</sup>

One explanation that might account for these discrepancies has to do with the impact of treatment itself. In RRMS, IFN  $\alpha$ -2a did not improve QoL after 6months; however, adverse events were significantly correlated with several SF36 sub-scales.<sup>18</sup> Thus the side effects of treatment with IFN negatively impact MS QoL thereby confounding the potential benefits of disease modifying treatment.

To date the only US FDA approved treatment for MS that showed a benefit on MS QoL is natalizumab.<sup>19</sup> In a 2 year RCT, treatment with natalizumab resulted in a 2 point difference in the PCS score, and a 2.5 point difference in the MCS score, of the SF36 relative to placebo. In a second 2 year RCT, treatment with natalizumab plus IFN  $\beta$ -1a resulted in a 2 point difference in the PCS score and a 1 point difference in the MCS score relative to IFN  $\beta$ -1a alone. Although a five point change on either the MCS or PCS of the SF-36 is proposed to be the clinically relevant magnitude of change, the correlation between 2 point changes on these scales with objective measures of clinical efficacy in these two natalizumab clinical trials suggests that smaller changes may be clinically important for MS patients.

The effect of LDN on the mental component summary score of the SF-36 compares favorably to that of natalizumab suggesting that the magnitude of difference relative to placebo for this measure is clinically relevant (a 3.3 point increase at 8 weeks for LDN compared to a 1.0 to 2.5 point increase at 2 years for natalizumab). This benefit for LDN treatment was supported by significant improvements on the mental health inventory (6 points), the pain effects scale (1.6 points) and the perceived deficits questionnaire (2.4 points). Because disease modifying treatments have not demonstrated an effect on these scales it is unknown how clinically relevant are these magnitudes of change.

Nevertheless, the proportion of improvement on these other scales is similar to that of the MCS score of the SF-36.

That LDN had benefit with regard to patient reported mental health, pain and cognitive function raises the possibility that patients became unmasked to treatment. This however cannot explain the findings because unmasking with respect to treatment arm would be expected to abrogate the benefits of placebo and therefore the placebo QoL measures would either be the same or worse than baseline. In fact, these measures were better than baseline in both groups (Figure). Moreover, exit interviews conducted in a sample of the cohort confirmed that subjects were not able to guess the order of treatment.

Regression modeling showed that neither IFN nor GA treatment influenced QoL in this study. Because patients were required to be on treatment with these drugs for at least three months prior to enrollment any effect of these drugs on QoL indices was likely preset at baseline and thus would not influence the study results. Furthermore, the lack of effect of IFN or GA on the outcomes suggests that there is not a negative interaction between these drugs and LDN. Interestingly, the only baseline variable that influenced the outcome measures was the baseline MSQLI scores. Subjects who experienced a poorer quality of life at baseline were more likely to benefit from treatment.

Despite the provocative observations that LDN may symptomatically improve the some aspects of quality of life in MS patients, it must be emphasized that the present study design did not assess LDN as a disease modifying therapy. The results do not support use of LDN as an alternate to proven MS treatments such as interferon beta, glatiramer acetate and natalizumab. Indeed, there is a misconception among some MS patients that LDN is incompatible with interferon usage and the present study did not find evidence of

such antagonism. In conclusion, in this exploratory, single center study, 8 weeks of treatment LDN was associated with symptomatic benefit with respect to mental health, pain and perceived cognitive deficits in MS. Confirmation of these findings in a multi center trial will be necessary to make definite conclusions about the possible symptomatic benefit of LDN in MS. A longer duration of treatment is necessary to determine whether LDN has any benefit with respect to physical outcome measures. Immunological and endorphin studies may help elucidate the mechanism of action of LDN responsible for these observations.

**Acknowledgments**

We are grateful to the MS patients for participating in this study and to Sammy Jo Wilkinson of Idners.org and other fundraisers who made this trial possible through an unrestricted gift to the UCSF MS Center. The patient sponsors of this study did not participate in the design, conduct, or analysis of the trial and did not help write the manuscript. To our knowledge this is the first patient funded clinical trial in MS. We are also grateful to Michael Jarrett from QuesGen Systems for constructing the web based application of the MSQI and for data management, Joanne Whitney and Scott Fields and for their expertise in compounding and investigational pharmacy and Michael Ross, Ivo Violich, Brendan Berry, and Azadeh Beheshtian, for their assistance in running the trial.

## References

1. Hamann S, Sloan P. Oral naltrexone to enhance analgesia in patients receiving continuous intrathecal morphine for chronic pain: a randomized, double-blind, prospective pilot study. *J Opioid Manag.* 2007;3:137-44
2. Webster LR, Butera PG, Moran LV, Wu N, Burns LH, Friedmann N. Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. *J Pain.* 2006;9:937-946
3. Mannelli P, Patkar AA, Peindl K, Gorelik DA, Wu L-T, Gottheli E. Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial. *Addiction Biology.* 2008; 14:204-213
4. Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn's disease. *Am J Gastroenterol.* 2007;102:820-8
5. Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher ME, Corsi M, Franchi S, Martinelli V, Nemni R, Comi G and Martino G A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. *Multiple Sclerosis* 2008; 14: 1076–1083
6. The Consortium of Multiple Sclerosis Centers Health Services Research Subcommittee. *Multiple Sclerosis Quality of Life Inventory: a user's manual.* New York: National Multiple Sclerosis Society, 1997.
7. Riazi A, Hobart JC, Laping DL, et al. Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles. *J Neurol Neurosurg Psychiatry* 2003;74:710 –714.
8. Ware JE, Sherbourne CD. The MOS SF-36 Short-Form Health Survey (SF-36). Conceptual framework and item selection. *Med Care* 1992;30:473– 481.
9. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology* 33: 1444-528.
10. Arnoldus JH, Killestein J, Pfenning LE, Jelles B, Uitdehaag BM, Polman CH. Quality of life during the first 6 months of interferon-beta treatment in patients with MS. *Mult Scler* 2000;6:338-342
11. Moore E and Wilkinsons S. *The promise of naltrexone therapy. Potential benefits in cancer, autoimmune, neurological and infectious disease.* 2008. McFarland Publishing. Jefferson, NC.
12. Vermersch P, De Seze J, Delisse B, Lemaire S, Stojkovic T. Quality of life in multiple sclerosis: influence of interferon beta therapy. *Mult Scler* 2002;8:377-381

13. Haupts M, Elias G, Hardt C, Langenbahn H, Obert H, Pöhlau D, Sczesni B, von Wussow P. Quality of life in patients with remitting-relapsing multiple sclerosis in Germany. *Nervenarzt* 2003;74:144-150
14. Zivadinov R, Zorzon M, Tommasi MA, Nasuelli D, Bernardi M, Monti-Bragadin L, Cazzato G. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. *J Neurol Sci* 2003;216:113-118
15. Schwartz CE, Coulthard-Morris L, Cole B, Vollmer T. The quality-of-life of interferon beta-1b in multiple sclerosis. An extended Q-TWIST analysis. *Arch Neurol* 1997;54:1475-1480
16. Freeman JA, Thompson AJ, Fitzpatrick R, Hutchinson M, Mittenburger C, Beckmann K, Dahlke F, Kappos L, Polman C, Pozzilli C, European study group on interferon beta-1b in secondary progressive MS. *Neurology* 2001;57:1870-1875
17. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MD, Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN, IMPACT Investigators. Benefit of interferon beta-1a on MSFC progression in secondary progressive multiple sclerosis. *Neurology* 2002;59:679-687
18. Nortvedt MW, Riise T, Myhr KM, Nyland HI, Hanestad BR. Type I interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a. *Mult Scler* 1999;5:317-322
19. Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Waigt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, AFFIRM and SENTINEL Investigators. Health related quality of life in multiple sclerosis: effects of natalizumab. *Annal Neurol* 2007;62:335-346

Table 1 Baseline Demographics

Mean age	49
Women: Men	36:24
Race	White 54, Asian 2, Multi-racial 2, not specified 2
RRMS	31
SPMS	13
PPMS	15
PRMS	2
Concurrent IFN use	14
Concurrent GA use	14
No Concurrent DMT	32

Scale	Baseline	Subscale Range	Placebo	LDN	$\Delta$ LDN- Placebo	P-value
SF-36 PCS	34.98	13.6-61.9	36.85	36.95	0.10	0.88
SF-36 MCS	44.32	15.6-70.0	46.77	50.07	3.30	0.04
PF	44.40	0-100	45.90	47.82	1.92	0.18
RP	25.42	0-100	36.00	43.08	7.08	0.18
BP	63.34	0-100	66.70	68.83	2.13	0.42
GH	50.76	0-100	52.78	52.46	-0.32	0.85
VT	33.60	0-90	42.60	44.72	1.92	0.52
SF	57.80	12.5-100	69.90	69.69	-0.21	0.95
RE	53.67	0-100	55.37	69.81	14.44	0.03
MH	65.22	0-100	66.92	72.12	5.2	0.02
MFIS	38.6	0-84	31.41	30.28	-1.13	0.53
PES	16.1	6-30	14.17	12.60	-1.57	0.04
SSS	9.7	4-24	9.14	8.97	-0.17	0.76
BLCS	5.1	0-22	4.44	5.06	0.62	0.17
BWCS	3.3	0-26	3.02	3.29	0.27	0.79
IVIS	1.7	0-15	1.42	1.47	0.05	0.83
PDQ	27.6	0-80	25.20	22.78	-2.42	0.05
MHI	63.5	0-100	65.65	71.65	6.00	<0.01
MSSS	77.1	0-100	72.76	74.11	1.35	0.43

Table 2: MSQLI results SF-36 PCS=short form 36 Physical Component Summary scale,

SF-36 MCS= short form 36 Mental Component Summary scale, PF=Physical

Functioning, RF=Role-Physical, BP=Bodily Pain, GH=General Health, V=Vitality, SF=Social Functioning, RE=Role-Emotional, MH=Mental Health, MFIS=Modified Fatigue Impact Scale, PES=Pain Effects Scale, SSS=Sexual Satisfaction Survey, BLCS=Bladder Control Scale, BWCS=Bowel Control Scale, IVIS=Impact of Visual Impairment Scale, PDQ=Perceived Deficits Questionnaire, MHI=Mental Health Inventory, MSSS=Multiple Sclerosis Social Support Survey. The range is for the subscales rather than the range reported for the subjects in the study at baseline.

Accepted Preprint

Accepted Preprint




Figure 1: Study Design  
33x13mm (600 x 600 DPI)




Figure 2: SF-36, PCS=physical component summary scale score, range 13.6 - 61.9 baseline 34.9.  
MCS=mental component summary scale score, range 15.6 - 70.0, baseline 44.2.  
35x15mm (600 x 600 DPI)




Figure 3: PES=pain effects scale, range 6 – 30, baseline 16.1. MHI=mental health inventory, range 0 – 100, baseline 63.5  
34x15mm (600 x 600 DPI)

Accepted Preprint